Expert Interviews

Ali Tafreshi discusses Oku Digital Health, launched from Topcon to link eye care with primary care, and the barriers ahead.

At EURETINA 2026, David Steel reviewed registry evidence on gas and silicone oil tamponades for retinal detachment repair and outlined novel tamponade agents in his Kreissig Award Lecture.

Sunir Garg, MD, FACS, previews DME and dry AMD data, free papers, and surgical sessions at AAO 2026.

Ritesh Narula, MBBS, MS, discusses phase 1 and early phase 2 results of the Eyestem subretinal stem cell study in geographic atrophy, including an 11-letter mean visual acuity gain maintained at 18 months.

At EURETINA 2026, Arshad Khanani, MD, FASRS, reviews sura-vec, 4D-150 and ixo-vec, 3 nAMD gene therapies in phase 3 with readouts expected over the next 12 months.

João Pedro Marques, MD, MSc, PhD, FEBOphth, discusses the IRD-PT, a web-based Portuguese registry of roughly 2,400 patients with inherited retinal diseases that supports research and identifies patients for clinical trials.

At EURETINA 2026, Elon van Dijk, MD, PhD, FEBOphth, reviewed trial evidence favouring half-dose PDT over micropulse laser and eplerenone for central serous chorioretinopathy.

Paul Nderitu, MBChB, MPhil, MBCS, FRCOphth, PhD, gives an update at EURETINA 2026 on Global RETFound, a foundation model being built with 108 partners from more than 40 countries

Katherine Talcott, MD, discusses phase 2 VERONA results showing EYP-1901 plus aflibercept reduced supplemental treatment needs in DME, with early vision and anatomy gains and no significant safety signals.

OT Roundup returns with MOGENRY's 4-year RP data, RCA's retina care report, SYD-101's FDA hearing, and new OCU410 GA data.

Francesca Cordeiro, PhD, MD, FRCOphth, explains how Detection of Apoptosing Retinal Cells (DARC) imaging predicted the speed and direction of GA growth and could help stratify patients for treatment.

For CVI Awareness Day, 3 experts explain why CVI can hide behind a normal eye exam and why early referral matters.

Cathleen McCabe, MD, presents real-world data from a 57-site US study of the enVista Aspire IOL at ESCRS 2026, reporting over 90% patient satisfaction and 20/32 uncorrected intermediate vision in more than 70% of patients.

Nimesh A. Patel, MD, explains why myopia-related retinal detachments are appearing earlier and how routine exams can catch them.

Uday Devgan, MD, FACS, co-chair of EyeCon 2026, highlights what makes cataract surgery challenging, when to add MIGS, and why no patient is routine.

Nimesh A. Patel, MD, discusses compounded low-dose atropine and SYD-101 ahead of an October 30 FDA advisory committee meeting.

At ESCRS 2026, Jascha Wendelstein, MD, noted standard ETDRS visual acuity testing misses functional differences between multifocal IOLs that reading-speed testing reveals.

Helena Noguera Nuñez, MD, discusses a prospective study of the TECNIS Odyssey IOL from ESCRS 2026.

Samantha Harding, MD, discusses how ultra-widefield imaging reduces dilation needs and improves diagnosis in paediatric eye care.

Hove stresses surgeons who prescribe premium lenses or laser surgery to patients should be willing to have those same treatments themselves when needed.

Ana Miguel, MD, PhD, explains how artificial intelligence already outperforms experts in glaucoma screening, expands telemedicine access, and reshapes patient conversations.

Giuseppe Giannaccare, MD, PhD, FEBOphth, discusses new data on perioperative low-level light therapy for post-cataract dry eye at ESCRS 2026.

Anat Loewenstein, MD, previews EURETINA 2026 Vienna: the Innovation Spotlight, 17 sessions, symposia, and more.

Ashraf Ahmad, MD, explains what's driving rising dry eye rates and why eyelid evaluation is often overlooked.

At ESCRS 2026, Imane Tarib, MD discusses fostering inclusive ophthalmology workplaces and mentorship for early-career surgeons.

OT Roundup debuts with new ADHD ocular findings, a surgeon's own trifocal IOL journey, MOGENRY's FDA filing, and myopia policy news.

ESCRS 2026 data: patient selection and education may be key to aceclidine (VIZZ; LENZ Therapeutics) persistence.

Adam Muzychuk, MD, discusses how AI like the Kane formula is improving outcomes, and why he still urges caution over relying on it for clinical decisions.